Q-omics provides the consensus-scored ZNF875 profile across patient tissues and cancer cell-line models. ZNF875 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ZNF875 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, ZNF875 RNA expression shows 21,820 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, THCA, and ACC as cancer lineages where ZNF875 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF875 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF875 survival associations across molecular data types. ZNF875 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF875 RNA expression–survival associations across cancer types. High ZNF875 expression shows unfavorable associations in LGG and ACC, but favorable associations in BRCA, UCS, UVM and KIRP. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for ZNF875 RNA expression.
This table summarizes ZNF875 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF875. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF875 shows lower tumor expression in THCA and higher tumor expression in LIHC, BLCA, LUAD, CHOL and STAD. The THCA box plot shows higher ZNF875 RNA expression in normal versus tumor tissue (log2 FC = −0.464, t-test p < 0.001).
This table shows molecular features associated with ZNF875 in patient tissues and cancer cell lines. In patient samples, ZNF875 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF875 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
